Analyst consensus rating
Entrada Therapeutics, Inc. Analyst Rating: Strong Buy
TRDA is rated Strong Buy by 4 analysts with a $18.75 target. As of 2026-08-15.
Direct answer
Entrada Therapeutics, Inc.'s consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.75.
Forecast evidence checked August 15, 2026.
Get free Entrada Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.46
- Average price target
- $18.75
- High price target
- $25.00
- Low price target
- $10.00
- Target upside
- +151.3%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 15, 2026
- Valid through
- August 22, 2026